Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). The virus damages the immune system and thus interferes with the body’s ability to fight organisms that cause disease. HIV attacks immune cells, specifically CD-4 cells, and makes the body susceptible to infections and other diseases.
AIDS is a life-threatening and chronic disease that can be transmitted from one person to another through various routes, including sexual intercourse, direct injection with HIV-contaminated drugs, needles, syringes, blood or blood products, and from HIV-infected mothers to fetuses. As of now, no cure for AIDS. However, antiretroviral regimens (ARVs) are recommended for patients with HIV as it can dramatically slow the disease progression as well as prevent other infections and complications.
The increasing prevalence of HIV/AIDS worldwide catalyzes the growth of the global HIV drugs market. According to UNAIDS, in 2019, the total number of patients with HIV/AIDS was around 38 million across the globe. The adult and children population was 36.2 and 1.8 million, respectively.
Additionally, several initiatives are undertaken by governments/associations/organizations in respective countries and globally to educate and raise awareness, availability of generic HIV drugs, and new drug development and regulatory approvals for HIV treatment are expected to drive the market further. For instance, in March 2020, ViiV Healthcare, the subsidiary of GlaxoSmithKline, received regulatory approval for its long-acting regimen for the treatment of HIV; CABENUVA by Health Canada.
The Global HIV drugs market is segmented on the basis of product and region. Based on the product, the market is divided into Zolgensma, Atripla, Biktarvy, Complera, Delstrigo, Descovy, Dovato, Genvoya, Isentress, Juluca, Odefsey, Stribild, Symtuza, Tivicay, Triumeq, Trogarzo, Truvada, Cabotegravir/Rilpivirine, Fostemsavir, Leronlimab and Others.
Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that North America held the largest share of the market in 2019, followed by Europe and Asia Pacific. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period.
The key players in the market are Gilead Sciences, ViiV Healthcare, Janssen, Merck & Co., Bristol-Myers Squibb, TaiMed Biologics, CytoDyn, Boehringer Ingelheim International GmbH, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan among others.